70 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
XLRN Acceleron Pharma Inc. $52 $2.39B N/A
Article Searches
Celgene & Acceleron's BLA for Luspatercept Accepted by FDA http://www.zacks.com/stock/news/425862/celgene-accelerons-bla-for-luspatercept-accepted-by-fda?cid=CS-ZC-FT-425862 Jun 06, 2019 - Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.
Celgene (CELG) Presents Data on Pipeline Candidates at ASCO http://www.zacks.com/stock/news/424905/celgene-celg-presents-data-on-pipeline-candidates-at-asco?cid=CS-ZC-FT-424905 Jun 05, 2019 - Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.
Acceleron Pharma Inc (XLRN) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/05/09/acceleron-pharma-inc-xlrn-q1-2019-earnings-call-tr.aspx?source=iedfolrf0000001 May 09, 2019 - XLRN earnings call for the period ending March 31, 2019.
Acceleron Pharma's (XLRN) CEO Habib Dable on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4262279-acceleron-pharmas-xlrn-ceo-habib-dable-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare May 09, 2019 - Call Start: 17:00 Call End: 17:35 Acceleron Pharma, Inc. (NASDAQ:XLRN) Q1 2019 Earnings Conference Call May 9, 2019, 5:00 pm ET Company Participants Todd James - VP, IR & Corporate Communications
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More http://www.zacks.com/stock/news/411198/drug-biotech-stock-q1-earnings-on-may-9-ions-xlrn-more?cid=CS-ZC-FT-411198 May 08, 2019 - Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
5 Must-Buy Stocks Ahead of Q1 Earnings Amid Market Volatility http://www.zacks.com/stock/news/410878/5-must-buy-stocks-ahead-of-q1-earnings-amid-market-volatility?cid=CS-ZC-FT-410878 May 08, 2019 - First-quarter 2019 earnings results so far are better than expected.
Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings? http://www.zacks.com/stock/news/410389/will-life-sciences-sales-boost-bio-rads-bio-q1-earnings?cid=CS-ZC-FT-410389 May 07, 2019 - Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).
Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales http://www.zacks.com/stock/news/404541/celgene-celg-q1-earnings-beat-estimates-on-revlimid-sales?cid=CS-ZC-FT-404541 Apr 26, 2019 - Celgene (CELG) beats on earnings and sales in the first quarter of 2019.
Celgene & Acceleron Submit BLA for Luspatercept to the FDA http://www.zacks.com/stock/news/372710/celgene-acceleron-submit-bla-for-luspatercept-to-the-fda?cid=CS-ZC-FT-372710 Apr 08, 2019 - Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.
Acceleron Pharma (XLRN) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/28/acceleron-pharma-xlrn-q4-2018-earnings-conference.aspx?source=iedfolrf0000001 Feb 28, 2019 - SQ earnings call for the period ending December 31, 2018

Pages: 1234567

Page 1>